The Administrative Core (Core A) will continue to provide oversight of all SPORE activities including the Projects, Cores, Developmental Research Program, Career Development Program, and activities carried out under the auspices of SPORE supplements. The Core ensures compliance with all local, federal and NCI regulations and requirements. The Core is responsible for communication and consultation with NCI personnel in preparation of all required reports and publications. The Core is responsible for all fiscal and budgetary functions. The Core organizes all meetings including the monthly SPORE investigators meeting, meetings with the Executive Committee as well as the Internal and External Scientific Advisory Boards. The Core establishes and monitors policies for the recruitment of women and minorities, both as participants on SPORE trials, and also as SPORE investigators. The Core coordinates travel of SPORE investigators to all NCI-sponsored SPORE meetings. The Core interacts with the Developmental Research Program and the Career Development Program to ensure smooth functioning of these SPORE components. The Core coordinates activities with the University of Pittsburgh Cancer Institute to avoid redundancy and ensure that joint activities between the UPCI Head and Neck Cancer Program and the Head and Neck Cancer SPORE are carried out efficiently and that the programs are complementary and synergistic. The Administrative Core interacts with the NCI Program office to ensure that the SPORE guidelines are followed and that the mandate of the SPORE program is carried out. The Core also facilitates collaborations with the UPCI Lung Cancer SPORE and newly funded Skin SPORE as well as the Head and Neck Cancer SPORE programs at other institutions. In the prior funding period, the Core played a key role in changing project directions, developing new projects, and initiating collaborations with input from both the Internal and External Advisory Boards. These decisions led to the new projects proposed in this renewal application.
Coordination of the projects, cores and programs in this SPORE will be overseen by this Administrative Core. This will include scheduling of monthly meetings and facilitation of interactions with members of the lAB and EAB. Oversight activities will include monitoring of progress for each project, core, DRP pilot, and CDP candidate. These functions are critical for the operations of the SPORE.
|Albergotti, William G; Gooding, William E; Kubik, Mark W et al. (2017) Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. JAMA Otolaryngol Head Neck Surg 143:542-548|
|Jie, Hyun-Bae; Srivastava, Raghvendra M; Argiris, Athanassios et al. (2017) Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res 5:408-416|
|Kubik, Mark; Mandal, Rajarsi; Albergotti, William et al. (2017) Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery. Head Neck 39:1510-1515|
|Patel, Snehal G; Carty, Sally E; McCoy, Kelly L et al. (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery 161:168-175|
|Srivastava, Raghvendra M; Trivedi, Sumita; Concha-Benavente, Fernando et al. (2017) CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res 23:707-716|
|Concha-Benavente, Fernando; Ferris, Robert L (2017) Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 45:52-59|
|Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852|
|Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96|
|Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2017) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res :|
|Godse, Neal R; Khan, Nayel; Yochum, Zachary A et al. (2017) TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res 23:7324-7332|
Showing the most recent 10 out of 289 publications